GCase Activator

About Vanqua Bio

Vanqua Bio is a private, preclinical-stage biotech targeting neurodegenerative diseases through a novel approach centered on lysosomal biology and innate immune system modulation. The company's lead asset is a small molecule GCase activator aimed at Parkinson's disease, with a broader pipeline addressing idiopathic Parkinson's and Alzheimer's disease. Backed by experienced leadership and top-tier life science investors, Vanqua aims to develop disease-modifying therapies using patient-derived neuronal cell models to improve clinical translation.

About Vanqua Bio

Vanqua Bio is a private, preclinical-stage biotech targeting neurodegenerative diseases through a novel approach centered on lysosomal biology and innate immune system modulation. The company's lead asset is a small molecule GCase activator aimed at Parkinson's disease, with a broader pipeline addressing idiopathic Parkinson's and Alzheimer's disease. Backed by experienced leadership and top-tier life science investors, Vanqua aims to develop disease-modifying therapies using patient-derived neuronal cell models to improve clinical translation.

Therapeutic Areas